Ferrari C, Crosignani P G, Caldara R, Picciotti M C, Malinverni A, Barattini B, Rampini P, Telloli P
J Clin Endocrinol Metab. 1980 Jan;50(1):23-6. doi: 10.1210/jcem-50-1-23.
It has recently been claimed that the PRL-lowering response to nomifensine administration (200 mg, orally) reliably discriminates patients with PRL-secreting tumors from those with so-called functional hyperprolactinemia. In the present study, this test was performed in 15 healthy controls, 7 hyperprolactinemic subjects without evidence of pituitary tumor, and 16 patients with prolactinoma. A decrease of serum PRL to below 65% of basal levels, which seemed to be the cut-off point in the previous study, was obtained in 11 subjects of the first group, in 4 subjects of the second group, and in 4 subjects of the third group. The decrease of mean serum PRL concentration after nomifensine was only significant in the first and second groups. Analysis of variance showed a significant difference in the PRL inhibition by nomifensine between the tumor group and the two groups without evidence of pituitary adenoma. Nevertheless, this study shows that the nomifensine test is unable to discriminate in the individual patient the tumorous or nontumorous origin of excessive PRL secretion.
最近有人声称，口服200毫克诺米芬辛后催乳素降低反应能够可靠地区分催乳素分泌瘤患者与所谓功能性高催乳素血症患者。在本研究中，对15名健康对照者、7名无垂体瘤证据的高催乳素血症受试者以及16名催乳素瘤患者进行了该测试。第一组的11名受试者、第二组的4名受试者以及第三组的4名受试者血清催乳素降至基础水平的65%以下，这似乎是先前研究中的临界点。诺米芬辛给药后平均血清催乳素浓度的降低仅在第一组和第二组中具有显著性。方差分析显示，肿瘤组与两组无垂体腺瘤证据的组之间，诺米芬辛对催乳素的抑制存在显著差异。然而，本研究表明，诺米芬辛试验无法在个体患者中区分催乳素分泌过多的肿瘤性或非肿瘤性来源。
